News

September 21, 2022

EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications

  EIP Pharma Publishes Translational Data of Preclinical and Phase 2a Results for Neflamapimod in Dementia with Lewy Bodies: Nature Communications – Neflamapimod demonstrates that it reverses the neurodegenerative process in the basal forebrain cholinergic system in animal models – – Phase 2a data in Dementia with Lewy Bodies show positive effects of neflamapimod on […]

Read More

November 10, 2021

Presentation at 14th CTAD Conference November 10, 2021

EIP Pharma announces that final results of the AscenD-LB phase 2 clinical study demonstrates neflamapimod has disease-modifying potential in dementia with Lewy Bodies   Results presented at 14th Clinical Trials in Alzheimer’s Disease (CTAD) meeting in Boston   Neflamapimod treatment led to significant improvement relative to placebo in cognition, motor function, and cognition & function […]

Read More

November 4, 2021

EIP Pharma Announces New Data Presentations from Phase 2 Treatment Trial in Dementia with Lewy Bodies at Upcoming Scientific Conference and New Board Appointment

Final results of the AscenD-LB clinical study informs on disease-modifying potential of neflamapimod in dementia with Lewy bodies Presentations at 14th Clinical Trials in Alzheimer’s Disease Meeting, November 9-12, 2021 BOSTON, Nov. 4, 2021 /PRNewswire/ — EIP Pharma Inc., a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative diseases announces that the […]

Read More

View All News



Presentations


View All Presentations

About EIP

Are you a patient, caregiver, clinician or professional and want to learn more about EIP Pharma’s approach? Please contact us.

Contact Us